PHOENIX

PHOENIX is an EU Cancer Mission project dedicated to improving treatment options for children with high-risk cancers, including neuroblastoma and other aggressive paediatric solid tumours. Despite advances in cancer care, many children with relapsed or treatment-resistant disease still face poor outcomes and severe long-term side effects from existing therapies.

The project focuses on the clinical development of ibrilatazar (ABTL0812), an innovative oral anticancer therapy designed to target tumour cells in a potentially safer way than conventional chemotherapy while sparing healthy DNA. Building on promising preclinical and adult clinical data, PHOENIX will conduct the first-in-child multicentre Phase I/II clinical trial of ibrilatazar in combination with standard treatments and selected immunotherapies.

Alongside the clinical trial, PHOENIX integrates advanced biomarker research, personalised medicine approaches, and studies on social determinants of health to improve patient stratification, treatment monitoring, inclusiveness, and quality of care.

By bringing together 13 partners from 6 countries, including leading researchers, clinicians, patient organisations, and innovation partners across Europe, PHOENIX aims to deliver safer and more effective therapeutic options and create new hope for children and families affected by high-risk cancers.

PHOENIX is part of the EU Cancer Mission cluster “Diagnosis and Treatment – Innovative clinical trials for paediatric cancer.”

Population: Paediatric | Intervention type: Interventional